Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0061614 | Colorectum | AD | pri-miRNA transcription by RNA polymerase II | 24/3918 | 55/18723 | 1.22e-04 | 1.78e-03 | 24 |
GO:1902893 | Colorectum | AD | regulation of pri-miRNA transcription by RNA polymerase II | 23/3918 | 54/18723 | 2.60e-04 | 3.25e-03 | 23 |
GO:00616142 | Colorectum | MSS | pri-miRNA transcription by RNA polymerase II | 19/3467 | 55/18723 | 3.47e-03 | 2.59e-02 | 19 |
GO:19028932 | Colorectum | MSS | regulation of pri-miRNA transcription by RNA polymerase II | 18/3467 | 54/18723 | 6.70e-03 | 4.38e-02 | 18 |
GO:00616143 | Colorectum | FAP | pri-miRNA transcription by RNA polymerase II | 21/2622 | 55/18723 | 7.50e-06 | 2.25e-04 | 21 |
GO:19028933 | Colorectum | FAP | regulation of pri-miRNA transcription by RNA polymerase II | 20/2622 | 54/18723 | 2.09e-05 | 5.05e-04 | 20 |
GO:0048016 | Colorectum | FAP | inositol phosphate-mediated signaling | 16/2622 | 55/18723 | 2.78e-03 | 2.15e-02 | 16 |
GO:1902894 | Colorectum | FAP | negative regulation of pri-miRNA transcription by RNA polymerase II | 7/2622 | 17/18723 | 5.62e-03 | 3.61e-02 | 7 |
GO:00616144 | Colorectum | CRC | pri-miRNA transcription by RNA polymerase II | 18/2078 | 55/18723 | 1.53e-05 | 4.70e-04 | 18 |
GO:19028934 | Colorectum | CRC | regulation of pri-miRNA transcription by RNA polymerase II | 17/2078 | 54/18723 | 4.62e-05 | 1.10e-03 | 17 |
GO:19028941 | Colorectum | CRC | negative regulation of pri-miRNA transcription by RNA polymerase II | 7/2078 | 17/18723 | 1.46e-03 | 1.57e-02 | 7 |
GO:0097720 | Colorectum | CRC | calcineurin-mediated signaling | 13/2078 | 48/18723 | 1.72e-03 | 1.77e-02 | 13 |
GO:0033173 | Colorectum | CRC | calcineurin-NFAT signaling cascade | 12/2078 | 43/18723 | 1.93e-03 | 1.96e-02 | 12 |
GO:00480161 | Colorectum | CRC | inositol phosphate-mediated signaling | 14/2078 | 55/18723 | 2.21e-03 | 2.15e-02 | 14 |
GO:00616146 | Liver | NAFLD | pri-miRNA transcription by RNA polymerase II | 13/1882 | 55/18723 | 2.64e-03 | 2.42e-02 | 13 |
GO:19028936 | Liver | NAFLD | regulation of pri-miRNA transcription by RNA polymerase II | 12/1882 | 54/18723 | 6.44e-03 | 4.69e-02 | 12 |
GO:006161412 | Liver | Cirrhotic | pri-miRNA transcription by RNA polymerase II | 22/4634 | 55/18723 | 8.94e-03 | 4.12e-02 | 22 |
GO:006161422 | Liver | HCC | pri-miRNA transcription by RNA polymerase II | 35/7958 | 55/18723 | 1.26e-03 | 6.92e-03 | 35 |
GO:190289312 | Liver | HCC | regulation of pri-miRNA transcription by RNA polymerase II | 34/7958 | 54/18723 | 1.92e-03 | 9.78e-03 | 34 |
GO:19028942 | Liver | HCC | negative regulation of pri-miRNA transcription by RNA polymerase II | 13/7958 | 17/18723 | 4.77e-03 | 2.02e-02 | 13 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0431014 | Prostate | BPH | Wnt signaling pathway | 50/1718 | 171/8465 | 3.11e-03 | 1.15e-02 | 7.14e-03 | 50 |
hsa05166112 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
hsa0421819 | Prostate | BPH | Cellular senescence | 60/1718 | 156/8465 | 1.07e-07 | 1.18e-06 | 7.32e-07 | 60 |
hsa05167112 | Prostate | BPH | Kaposi sarcoma-associated herpesvirus infection | 69/1718 | 194/8465 | 4.22e-07 | 4.10e-06 | 2.54e-06 | 69 |
hsa05163111 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa0513519 | Prostate | BPH | Yersinia infection | 49/1718 | 137/8465 | 1.65e-05 | 1.27e-04 | 7.86e-05 | 49 |
hsa05417112 | Prostate | BPH | Lipid and atherosclerosis | 66/1718 | 215/8465 | 1.68e-04 | 9.56e-04 | 5.92e-04 | 66 |
hsa0401013 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
hsa0516112 | Prostate | BPH | Hepatitis B | 52/1718 | 162/8465 | 2.42e-04 | 1.27e-03 | 7.85e-04 | 52 |
hsa0465912 | Prostate | BPH | Th17 cell differentiation | 36/1718 | 108/8465 | 9.75e-04 | 4.47e-03 | 2.76e-03 | 36 |
hsa05170110 | Prostate | BPH | Human immunodeficiency virus 1 infection | 60/1718 | 212/8465 | 2.96e-03 | 1.12e-02 | 6.92e-03 | 60 |
hsa0431015 | Prostate | BPH | Wnt signaling pathway | 50/1718 | 171/8465 | 3.11e-03 | 1.15e-02 | 7.14e-03 | 50 |
hsa0421826 | Prostate | Tumor | Cellular senescence | 61/1791 | 156/8465 | 2.00e-07 | 2.14e-06 | 1.33e-06 | 61 |
hsa0516629 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
hsa0516728 | Prostate | Tumor | Kaposi sarcoma-associated herpesvirus infection | 67/1791 | 194/8465 | 9.21e-06 | 7.81e-05 | 4.85e-05 | 67 |
hsa0516327 | Prostate | Tumor | Human cytomegalovirus infection | 74/1791 | 225/8465 | 2.27e-05 | 1.79e-04 | 1.11e-04 | 74 |
hsa0513524 | Prostate | Tumor | Yersinia infection | 48/1791 | 137/8465 | 1.11e-04 | 7.25e-04 | 4.49e-04 | 48 |
hsa0401022 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
hsa0541729 | Prostate | Tumor | Lipid and atherosclerosis | 65/1791 | 215/8465 | 9.79e-04 | 4.44e-03 | 2.75e-03 | 65 |
hsa0465922 | Prostate | Tumor | Th17 cell differentiation | 36/1791 | 108/8465 | 2.11e-03 | 8.42e-03 | 5.22e-03 | 36 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
NFATC3 | MAST | Colorectum | AD | RPS6KA5,UBA6-AS1,PRELID2, etc. | 2.43e-01 | |
NFATC3 | TH1 | Endometrium | ADJ | SMAGP,AC006064.2,S1PR1, etc. | 8.94e-03 | |
NFATC3 | CD8TEFF | Endometrium | Healthy | SMAGP,AC006064.2,S1PR1, etc. | 2.68e-02 | |
NFATC3 | BMEM | Endometrium | Healthy | SMAGP,AC006064.2,S1PR1, etc. | 1.43e-01 | |
NFATC3 | BMEM | Liver | NAFLD | ZSCAN5A,AC116366.3,BICRAL, etc. | 9.23e-02 | |
NFATC3 | AT1 | Lung | Healthy | HAX1,CLDN18,ADIRF, etc. | 1.30e-01 | |
NFATC3 | NK | Lung | IAC | BRWD3,TMEM14A,SBNO1, etc. | 4.77e-02 | |
NFATC3 | CD4TN | Lung | IAC | BRWD3,TMEM14A,SBNO1, etc. | 2.11e-01 | |
NFATC3 | CD8TEFF | Lung | MIAC | PPM1D,SAMD3,CCND3, etc. | 9.86e-02 | |
NFATC3 | CD8TCM | Lung | MIAC | PPM1D,SAMD3,CCND3, etc. | 3.66e-02 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NFATC3 | SNV | Missense_Mutation | novel | c.208N>T | p.His70Tyr | p.H70Y | Q12968 | protein_coding | deleterious(0.03) | benign(0.041) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
NFATC3 | SNV | Missense_Mutation | | c.1440G>T | p.Met480Ile | p.M480I | Q12968 | protein_coding | tolerated(0.35) | benign(0.101) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
NFATC3 | SNV | Missense_Mutation | novel | c.605N>T | p.Arg202Leu | p.R202L | Q12968 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A7-A26F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
NFATC3 | SNV | Missense_Mutation | rs772602157 | c.1652G>A | p.Arg551Gln | p.R551Q | Q12968 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NFATC3 | SNV | Missense_Mutation | | c.301N>C | p.Gly101Arg | p.G101R | Q12968 | protein_coding | deleterious(0) | benign(0.244) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
NFATC3 | SNV | Missense_Mutation | | c.2125G>C | p.Glu709Gln | p.E709Q | Q12968 | protein_coding | deleterious(0.01) | benign(0.358) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
NFATC3 | SNV | Missense_Mutation | | c.2314G>A | p.Glu772Lys | p.E772K | Q12968 | protein_coding | tolerated_low_confidence(0.98) | benign(0.098) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
NFATC3 | SNV | Missense_Mutation | | c.1970N>A | p.Gly657Glu | p.G657E | Q12968 | protein_coding | tolerated(0.9) | benign(0.027) | TCGA-E2-A1IH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
NFATC3 | SNV | Missense_Mutation | novel | c.3076A>T | p.Ile1026Phe | p.I1026F | Q12968 | protein_coding | deleterious_low_confidence(0) | benign(0.386) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NFATC3 | insertion | Frame_Shift_Ins | novel | c.2625_2626insT | p.Leu876SerfsTer25 | p.L876Sfs*25 | Q12968 | protein_coding | | | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |